Tejara Capital Ltd Raises Stake in QuidelOrtho Corporation $QDEL

Tejara Capital Ltd raised its holdings in QuidelOrtho Corporation (NASDAQ:QDEL) by 97.2% during the fourth quarter, HoldingsChannel reports. The firm owned 208,327 shares of the company’s stock after buying an additional 102,700 shares during the period. QuidelOrtho comprises about 1.4% of Tejara Capital Ltd’s investment portfolio, making the stock its 13th biggest holding. Tejara Capital Ltd’s holdings in QuidelOrtho were worth $5,950,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in QDEL. Invesco Ltd. grew its holdings in shares of QuidelOrtho by 87.0% during the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after buying an additional 1,352,503 shares during the last quarter. Newtyn Management LLC raised its stake in QuidelOrtho by 58.3% during the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after acquiring an additional 994,332 shares during the last quarter. State Street Corp lifted its position in QuidelOrtho by 23.3% during the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company’s stock worth $77,841,000 after acquiring an additional 510,291 shares during the period. Millennium Management LLC purchased a new position in shares of QuidelOrtho in the 3rd quarter valued at approximately $10,932,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of QuidelOrtho by 14.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company’s stock valued at $84,208,000 after purchasing an additional 350,636 shares during the last quarter. 99.00% of the stock is owned by hedge funds and other institutional investors.

QuidelOrtho Stock Performance

Shares of QDEL stock opened at $11.39 on Friday. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. The stock has a 50 day simple moving average of $14.98 and a 200-day simple moving average of $22.91. The company has a market cap of $776.68 million, a price-to-earnings ratio of -0.64 and a beta of 0.75. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The business had revenue of $619.80 million during the quarter, compared to analysts’ expectations of $665.23 million. During the same quarter last year, the firm earned $0.74 earnings per share. The firm’s quarterly revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts forecast that QuidelOrtho Corporation will post 1.83 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on QDEL shares. Wall Street Zen cut QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Sunday, April 12th. Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and lowered their price objective for the company from $35.00 to $12.50 in a research report on Thursday, May 7th. Zacks Research cut shares of QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 17th. UBS Group restated a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and an average target price of $14.88.

QuidelOrtho Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.